Literature DB >> 33752308

[Bladder cancer incidence, mortality and temporal trends in China].

H Z Li1, R S Zheng2, L B Du1, S W Zhang2, C Zhu1, W W Wei2, J He3.   

Abstract

Objective: To describe the epidemiological characteristics of bladder cancer in 2015 and temporal trends in China.
Methods: From 501 cancer registries in China, we collected data of cancer new cases, deaths and populations in 2015. After qualified, sex-specific, area-specific, age-specific and overall incidence/mortality rates (including age-standardized rates by Chinese standard population and by world standard population) and estimated cases of bladder cancer were calculated. Annual Percent Change (APC)/Average Annual Percent Change (AAPC) fitted from Log-line model was applied to evaluate the temporal trends of bladder cancer incidence/mortality rates from 1998 to 2015.
Results: Bladder cancer is the 13(th) most common cancer in China. The crude, age-standardized by China standard population and by world standard population rates were 5.80/10(5), 3.60/10(5) and 3.57/10(5) for incidence, and 2.37/10(5), 1.31/10(5) and 1.32/10(5) for mortality, respectively. The incidence of bladder cancer ranked 7(th) in male. The incidence and mortality of male were 3.8 and 4.0 times as high as those of female. Bladder cancer incidence in urban area was 1.4 times as high as that in rural area. Incidence in western areas and middle areas of China were similar, which were lower than that in eastern areas. Geographical distribution characteristics of mortality was along with incidence.Both incidence and mortality remained low before 45 and 55 years old, then they increased rapidly and peaked at 80-84 and over 85 years old age group. Temporal trend analysis suggested that bladder cancer incidence in China increased in 1998-2007 (APC=2.58, P<0.001), while decreased from 2007 to 2015 (APC=-3.82, P<0.001). Bladder cancer mortality declined gradually, with APCs for 1998-2003 and 2003-2015 of 3.65% (P=0.002) and 1.42% (P<0.001). Conclusions: Bladder cancer is one of the main cancers in China. Its epidemiological distributions varies among different sex, area and age group. Both incidence and mortality of bladder cancer decline. More efforts on tobacco control should be made, and awareness of early diagnosis and early treatment could be enhanced for the middle-aged and elderly.

Entities:  

Keywords:  Bladder neoplasms; Cancer registry; Incidence rate; Mortality rate

Mesh:

Year:  2021        PMID: 33752308     DOI: 10.3760/cma.j.cn112152-20200421-00362

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  9 in total

1.  An integrative approach for identification of smoking-related genes involving bladder cancer.

Authors:  Fang Gao; Huiqin Li; Zhenguang Mao; Yanping Xiao; Mulong Du; Shizhi Wang; Rui Zheng; Zhengdong Zhang; Meilin Wang
Journal:  Arch Toxicol       Date:  2022-10-12       Impact factor: 6.168

2.  Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive Bladder Cancer.

Authors:  Pei Zheng; Jianhua Zhang; Yahong Zhu; Xiaodong Guan; Jianwen Quan; Qi Li; Fen Yi
Journal:  Comput Intell Neurosci       Date:  2022-05-13

3.  4-Methoxydalbergione Inhibits Bladder Cancer Cell Growth via Inducing Autophagy and Inhibiting Akt/ERK Signaling Pathway.

Authors:  Haifang Du; Ting Tao; Simeng Xu; Changqiong Xu; Shan Li; Qiongli Su; Jing Yan; Bo Liu; Ran Li
Journal:  Front Mol Biosci       Date:  2022-02-16

4.  Can Routine Blood and Urine Parameters Reveal Clues to Detect Bladder Cancer? A Case-Control Study.

Authors:  Dan-Qi Wang; Juan Shuai; Hang Zheng; Zhong-Qiang Guo; Qiao Huang; Xiao-Feng Xu; Xiao-Dong Li; Hao Zi; Dao-Jing Ming; Xuan-Yi Ren; Xian-Tao Zeng
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

5.  The DeltaN p63 Promotes EMT and Metastasis in Bladder Cancer by the PTEN/AKT Signalling Pathway.

Authors:  Yong-Hua Tian; Yun-Feng He; Jin-Si Tan; Yu Jiang; Qiao Xu; Hong-Lin Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-12       Impact factor: 2.650

Review 6.  Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors.

Authors:  Ming Cai; Wei-Jian Ni; Ying-Hong Wang; Jing-Ji Wang; Hong Zhou
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

7.  Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-β signalling pathway.

Authors:  Yufei Dong; Dapeng Ding; Juebin Gu; Mingying Chen; Shijun Li
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

8.  A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.

Authors:  Jian-Xuan Sun; Chen-Qian Liu; Jin-Zhou Xu; Ye An; Meng-Yao Xu; Xing-Yu Zhong; Na Zeng; Si-Yang Ma; Hao-Dong He; Zong-Biao Zhang; Shao-Gang Wang; Qi-Dong Xia
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

9.  Efficacy of compound aluminum sulfate injection as a monotherapeutic regimen in non-muscle invasive bladder cancer patients: a retrospective single-arm cohort study.

Authors:  Guanren Zhao; Fei Yang; Qi Yang; Yalong Yang; Axiang Xu; Yonghe Chen; Chunxi Wang; Lindong Du; Baofa Hong; Lei Zhang; Wenying Wang; Yuchuan Hou; Xiaoqing Wang; Xinyuan Tong; Xiaoxiong Wang; Fenghua Xu
Journal:  Transl Androl Urol       Date:  2022-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.